Filing Flows › AbbVie (ABBV) › Capital expenditures
AbbVie (ABBV) capital expenditures by quarter
AbbVie's capital expenditures were $301M in Q3 2026 (third quarter 2026), -7% from Q2 2026. Over the last 7 quarters it ranged from $235M (Q1 2025) to $381M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $301M | -7% | -21% |
| Q2 2026 | $322M | +22% | +20% |
| Q1 2026 | $265M | -19% | +13% |
| Q4 2025 | $329M | -14% | — |
| Q3 2025 | $381M | +42% | — |
| Q2 2025 | $269M | +14% | — |
| Q1 2025 | $235M | — | — |
Q3 2026 at a glance
AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%, net earnings $4.2B, operating cash flow $7.6B. The chart follows the revenue to costs, profit and cash.
Questions
What is AbbVie's capital expenditures?
AbbVie's capital expenditures were $301M in Q3 2026 (third quarter 2026), -7% from Q2 2026.
How has AbbVie's capital expenditures changed?
Over the last 7 quarters it ranged from $235M (Q1 2025) to $381M (Q3 2025).